Regma Announces Executed Agreement with the Naval Medical Research Center -NMRC- of the U.S.

Business Editors

LONDON--(BUSINESS WIRE)--Aug. 21, 2002

Regma Bio Technologies Limited (Regma)(OTC BB:RBTL) wishes to announce the signing of a Cooperative Research and Development Agreement with the Naval Medical Research Center (NMRC), a division of the U.S. Navy, in Silver

The intention of the agreement is to exploit the potential biological assets and capabilities of Regma Bio Technologies, Ltd. with respect to the diagnostic and therapeutic treatment of Anthrax and to jointly discover and develop capabilities that are either novel or build on existing capabilities of both parties.

Regma, is a London, England based biotechnology company developing novel methods, agents, and technologies for the prevention and treatment of infectious diseases. Regma's overall strategy includes the development of drug systems, which can increase the bioavailability of the drug at a cellular level with the use of bacteriophage. Regma recently announced its collaboration with the Institut Pasteur de Lille, in Lille, France, under the direction of Dr. Pablo Bifani. The goal of the collaboration is in developing novel methods in the prevention and treatment of infectious disease, using bacteriophage, with a focus on Tuberculosis (TB). Information about Regma can be accessed through the corporate website www.regma.co.uk.

The NMRC is a division of the Department of the Navy, United States of America, located in Silver Spring, MD. The mission of NMRC is to conduct research, development, tests and evaluations, and disease surveillance, in order to enhance the health, safety, performance and deployment medical readiness of Navy and Marine Corps. Information about the NMRC, including its capabilities and core competencies can be accessed through the NMRC website at www.nmrc.navy.mil/nmrc.htm.

NOTE: Forward-looking statements in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties as discussed and identified from time to time in the Company's public filings which could cause actual results to differ materially from those discussed in the forward-looking statements and from historical results of operations. Readers are cautioned that forward-looking statements are not guarantees of future performance and that actual results might differ materially from those contained in any forward-looking statements. We do not assume the obligation to update any forward-looking statements.